EyePoint Inc
Graf
Viktig: Aksjeinvesteringer kan over tid gi positiv avkastning, men innebærer risiko. Du kan tape deler av eller hele investeringen. Historisk avkastning for denne aksjen er ikke en pålitelig indikator på fremtidig avkastning. Data fra eksterne leverandører gjengis uendret av Saxo. Se fullstendig ansvarsfraskrivelse for data.
Om EyePoint Inc
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
/ 